4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
14.70
-0.24 (-1.61%)
At close: Sep 3, 2026, 4:00 PM EDT
14.52
-0.18 (-1.22%)
After-hours: Sep 3, 2026, 6:02 PM EDT
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $3.78M in the quarter ending June 30, 2026, with 25,106.67% growth. This brings the company's revenue in the last twelve months to $92.01M, up 278,712.12% year-over-year. In the year 2025, 4D Molecular Therapeutics had annual revenue of $85.21M with 230,194.59% growth.
Revenue (ttm)
$92.01M
Revenue Growth
+278,712.12%
P/S Ratio
8.69
Revenue / Employee
$469,429
Employees
196
Market Cap
812.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 85.21M | 85.17M | 230,194.59% |
| Dec 31, 2024 | 37.00K | -20.69M | -99.82% |
| Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
| Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
| Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
| Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
| Dec 31, 2019 | 6.99M | -7.14M | -50.56% |
| Dec 31, 2018 | 14.13M | 8.34M | 144.04% |
| Dec 31, 2017 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Theravance Biopharma | 104.31M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| DBV Technologies | 5.04M |
FDMT News
- 9 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - B. Riley views EyePoint study miss as positive for 4D Molecular - TheFly
- 18 days ago - 4D Molecular price target lowered to $32 from $33 at Goldman Sachs - TheFly
- 20 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 21 days ago - 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 21 days ago - 4D Molecular Therapeutics Quarterly report: Q2 2026 - Filings
- 21 days ago - 4D Molecular Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - 4D Molecular initiated with a Buy at B. Riley - TheFly